Serum Levels of Natriuretic Peptides in Children before and after Treatment for an Atrial Septal Defect, a Patent Ductus Arteriosus, and a Coarctation of the Aorta-A Prospective Study.
Background and Objectives. We evaluated and compared the influence of treatment for atrial septal defect (ASD), patent ductus arteriosus (PDA), and coarctation of the aorta (CoA) on serum levels of N-terminal proatriopeptide and N-terminal probrain natriuretic peptide. Correlations between peptide levels and echocardiographic measurements were calculated. Patients and Methods. Peptide levels were measured and echocardiography performed before and 6-12 months after treatment in 21 children with ASD, 25 with PDA, 15 with CoA, and 76 control children. Results. ANPN levels were higher than in controls at baseline in all patient groups, and NT-proBNP in patients with ASD and PDA. Both peptide levels were elevated 6 months after treatment and decreased thereafter. Peptide levels were higher in patients with volume than pressure overload. They correlated with echocardiographic measurements. At the 6-month follow-up, dimensions of the originally overloaded ventricle had normalized only in patients with PDA. Conclusions. After intervention, peptide levels decrease but normalization takes over 6 months. The type of correlation between peptide levels and echocardiography varies according to the loading condition. Measurement of peptide levels can be used for monitoring the course of a patient's heart disease.
Eerola
Anneli
A
Department of Pediatrics, University Hospital of Tampere, 33521 Tampere, Finland.
Jokinen
Eero
E
Boldt
Talvikki
T
Mattila
Ilkka P
IP
Pihkala
Jaana I
JI
Cardiol Young. 2005 Aug;15(4):396-401
16014188
Heart. 2000 Jun;83(6):667-72
10814626
Scand Cardiovasc J. 2007 Dec;41(6):370-7
17852783
Cathet Cardiovasc Diagn. 1998 Sep;45(1):27-32
9736347
J Am Coll Cardiol. 2006 Mar 7;47(5):1060-6
16516094
Heart. 2003 Aug;89(8):875-8
12860862
Am J Cardiol. 2004 Jun 1;93(11):1374-7, A6
15165917
Curr Probl Pediatr. 1998 Feb;28(2):33-60
9551314
Am J Cardiol. 1994 Apr 1;73(9):698-701
8166068
Pediatr Cardiol. 1997 Mar-Apr;18(2):96-100
9049120
Circulation. 1981 Jun;63(6):1315-22
7226477
Am J Cardiol. 1975 Sep;36(3):302-8
1166835
Am J Cardiol. 1982 Jul;50(1):143-8
7090997
Circulation. 1977 Mar;55(3):479-84
138489
Pediatr Cardiol. 2004 Jul-Aug;25(4):336-40
14735252
Acta Paediatr. 2002;91(6):649-52
12162595
Acta Paediatr. 2004 Mar;93(3):340-5
15124836
J Pediatr. 1987 Sep;111(3):335-42
2957477
Am J Cardiol. 2001 Mar 15;87(6):748-52
11249895
Heart. 2000 Sep;84(3):320-6
10956299
Eur J Heart Fail. 2000 Jun;2(2):161-5
10856729
Pediatrics. 1988 Oct;82(4):639-43
2971922
Eur J Endocrinol. 1995 Aug;133(2):207-9
7655645
Scand J Clin Lab Invest. 2004;64(5):497-510
15276915
J Am Coll Cardiol. 2001 Jun 15;37(8):2108-13
11419895
Am J Cardiol. 2001 Dec 15;88(12):1450-3, A9
11741575
Pediatr Cardiol. 1992 Jul;13(3):152-8
1603715
Eur J Clin Invest. 2002 Aug;32(8):563-9
12190955
Curr Probl Cardiol. 2004 Dec;29(12):707-69
15550914
Clin Chem. 2003 Sep;49(9):1563-4
12928255
Clin Physiol Funct Imaging. 2005 Sep;25(5):263-9
16117728
Acta Paediatr. 2004 May;93(5):603-7
15174780
Pediatrics. 2003 Oct;112(4):896-9
14523183
Ann Thorac Surg. 2004 Jan;77(1):53-60
14726034
J Am Coll Cardiol. 1994 Jul;24(1):194-200
8006265
Pediatr Res. 1986 Dec;20(12):1328-31
2948147
N Engl J Med. 1990 Dec 13;323(24):1698-700
2233967
Clin Sci (Lond). 2004 Sep;107(3):297-302
15142035
Am J Cardiol. 1978 Mar;41(3):487-93
626126
J Card Fail. 2005 Jun;11(5 Suppl):S81-3
15948107
Am J Cardiol. 2005 May 15;95(10):1255-7
15878007
Curr Med Chem Cardiovasc Hematol Agents. 2005 Apr;3(2):87-98
15853696
Catheter Cardiovasc Interv. 2007 Feb 15;69(3):432-41; discussion 442
17195197
Am J Cardiol. 2005 Feb 15;95(4):545-6
15695153
Can J Physiol Pharmacol. 2001 Aug;79(8):705-14
11558679
Br Heart J. 1970 Nov;32(6):820-6
5212356